AstraZeneca’s Imfinzi meets primary endpoint for liver cancer treatment
AstraZeneca has announced positive results from the EMERALD-1 phase 3 trial for Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) and bevacizumab for the treatment of patients with hepatocellular carcinoma (HCC) eligible for embolisation.
The trial showed a statistically significant and clinically meaningful improvement in the primary endpoint of progression free survival (PFS) compared to TACE alone for this indication. The trial will continue in order to assess its secondary endpoint of overall survival (OS).
Safety profiles for Imfinzi and TACE plus bevacizumab remained consistent with the drugs’ known profiles, with no new safety findings emerging.
Full data from the trial is expected to be presented at an upcoming medical meeting as well as being shared with the relevant regulatory authorities.
Susan Galbraith, executive vice president, Oncology Research and Development at AstraZeneca, commented: “These positive results for Imfinzi-based treatment in EMERALD-1 may bring the potential of immunotherapy to patients with earlier stages of liver cancer. We look forward to discussing these data with regulatory authorities and seeing the survival data mature over time, which will be important as we aim to bring this novel treatment option to patients.”
Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance
Tolremo Therapeutics has announced that it has dosed the first patient in its first-in-human clinical …
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …